RecruitingPhase 2NCT06824883

Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma

Studying Extranodal nasal NK/T cell lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking Union Medical College Hospital
Intervention
Immunochemotherapy(drug)
Enrollment
49 target
Eligibility
18-75 years · All sexes
Timeline
20242027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06824883 on ClinicalTrials.gov

Other trials for Extranodal nasal NK/T cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Extranodal nasal NK/T cell lymphoma

← Back to all trials